Watch BFRIW. Know when insiders buy.
One email the day a filing lands. Free.
BFRIW
Biofrontera Inc.
No price history available
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E —DIV YIELD —FCF YIELD —REV TTM $46.2M +17.8%NET INCOME −$6.4MNET CASH —52W —SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $12M | +32.9% | — | −$524K | −$604K | — | -0.05 | −$1.7M | $0 | −$1.7M | Aug 13 |
| Q1 2026 · Mar 31 | $10.1M | +17.4% | — | −$4.3M | −$4.8M | — | -0.41 | −$70K | $5K | −$75K | May 14 |
| Q4 2025 · Dec 31derived | $17.1M | +36.2% | — | $4.6M | $5.6M | — | 0.63 | −$2.4M | −$1K | −$2.4M | Mar 19 |
| Q3 2025 · Sep 30 | $7M | −22.5% | — | −$6.3M | −$6.6M | — | -0.62 | −$3.8M | −$1K | −$3.8M | Nov 12 |
| Q2 2025 · Jun 30 | $9M | +15.2% | — | −$5.1M | −$5.3M | — | -0.57 | −$3M | $1K | −$3M | Aug 13 |
| Q1 2025 · Mar 31 | $8.6M | +8.5% | — | −$4.5M | −$4.2M | — | -0.47 | −$4.1M | $3K | −$4.1M | May 14 |
| Q4 2024 · Dec 31derived | $12.6M | +18.5% | — | −$1.7M | −$1.4M | −139.6% | 0.17 | −$1M | $1K | −$1M | Mar 19 |
| Q3 2024 · Sep 30 | $9M | +1.3% | — | −$5M | −$5.7M | — | -0.98 | −$1.2M | $0 | −$1.2M | Nov 12 |
| Q2 2024 · Jun 30 | $7.8M | — | — | −$5.1M | −$257K | — | -0.05 | −$4.7M | −$48K | −$4.7M | Aug 13 |
| Q1 2024 · Mar 31 | $7.9M | — | — | −$5.5M | −$10.4M | — | -2.88 | −$3.3M | $57K | −$3.4M | May 15 |
| Q4 2023 · Dec 31derived | $10.6M | — | — | −$3.9M | $3.5M | — | 4.55 | −$8.9M | −$9K | −$8.9M | Mar 20 |
| Q3 2023 · Sep 30 | $8.9M | — | — | −$4.6M | −$6.3M | — | -4.64 | −$2M | $0 | −$2M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $41.7M | — | −$11.3M | −$10.5M | -25.3% | -1.04 | −$13.4M | $2K | −$13.4M | — | — |
| FY2024 · to Dec 31 | $37.3M | — | −$17.2M | −$17.8M | -47.6% | -3.22 | −$10.3M | $10K | −$10.3M | — | — |
| FY2023 · to Dec 31 | $34.1M | — | −$22.7M | −$20.1M | -59.1% | -13.02 | −$24.9M | $5K | −$24.9M | — | — |
| FY2022 · to Dec 31 | $28.7M | — | −$18.6M | −$640K | -2.2% | -0.61 | −$16.2M | $38K | −$16.2M | — | — |
| FY2021 · to Dec 31 | $24.1M | — | −$25.2M | −$37.7M | -156.5% | -4.28 | −$26.7M | — | — | — | — |
| FY2020 · to Dec 31 | $18.8M | — | −$9.6M | −$11M | -58.3% | -479.48 | −$12.4M | — | — | — | — |
Every number comes from Biofrontera Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.